{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:13:20Z","timestamp":1788470000027,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Landmark trials have shown that axillary lymph node dissection (ALND) can be safely omitted in early breast cancer patients with 1\u20132 positive nodes. Despite lack of prospective data, the National Comprehensive Cancer Network (NCCN) guidelines recommend that patients with 1\u20132 suspicious or biopsy-proven positive lymph nodes having primary surgery can undergo sentinel lymph node biopsy (SLNB). In the era of de-escalation of axillary surgery, breast cancer management in patients with clinically node-positive (cN\u2009+) axilla is driven by tumour biology and response to neoadjuvant chemotherapy (NACT). In this review, we discuss the management of the axilla in early breast cancer patients with low-volume biopsy-proven nodal disease and summarise the evidence supporting omission of ALND in these patients undergoing primary surgery.<\/jats:p>","DOI":"10.1186\/s43046-025-00318-7","type":"journal-article","created":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T23:02:31Z","timestamp":1758495751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["De-escalating axillary surgery in node-positive early breast cancer patients undergoing primary surgery: current evidence and recommendations"],"prefix":"10.1186","volume":"37","author":[{"given":"Hussain","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Alsendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"318_CR1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927\u201333.","journal-title":"Lancet Oncol"},{"key":"318_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546\u201353.","journal-title":"N Engl J Med"},{"key":"318_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297\u2013305.","journal-title":"Lancet Oncol"},{"key":"318_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569\u201375.","journal-title":"JAMA"},{"key":"318_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310.","journal-title":"Lancet Oncol"},{"key":"318_CR6","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1556\/OH.2013.29765","volume":"154","author":"A Savolt","year":"2013","unstructured":"Savolt A, Musonda P, Matrai Z, et al. Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial. Orv Hetil. 2013;154:1934\u201342.","journal-title":"Orv Hetil"},{"key":"318_CR7","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1245\/s10434-022-11866-w","volume":"29","author":"C Tinterri","year":"2022","unstructured":"Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29:5732\u201344.","journal-title":"Ann Surg Oncol"},{"key":"318_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryd\u00e9n L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390:1163\u201375.","journal-title":"N Engl J Med"},{"key":"318_CR9","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer: Ontario health (Cancer Care Ontario) and ASCO guideline. J Clin Oncol. 2021;39:3056\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"318_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1245\/s10434-024-16321-6","volume":"32","author":"R Matar-Ujvary","year":"2025","unstructured":"Matar-Ujvary R, Sevilimedu V, Morrow M. Are clinically node-negative patients with a positive preoperative axillary lymph node biopsy appropriate candidates for sentinel lymph node biopsy? Ann Surg Oncol. 2025;32(1):92\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"318_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331\u201357.","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"318_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA"},{"key":"318_CR13","doi-asserted-by":"publisher","first-page":"117822342098037","DOI":"10.1177\/1178223420980377","volume":"14","author":"M Asaoka","year":"2020","unstructured":"Asaoka M, Gandhi S, Ishikawa T, et al. Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast Cancer (Auckl). 2020;14:1178223420980377.","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"318_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41523-022-00432-y","volume":"8","author":"M El-Tamer","year":"2022","unstructured":"El-Tamer M, Kovacs T. Management of the axilla in T1\u20132N1 breast cancer. NPJ Breast Cancer. 2022;8(1):69.","journal-title":"NPJ Breast Cancer"},{"issue":"25","key":"318_CR15","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"318_CR16","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/1097-0142(197706)39:6<2827::AID-CNCR2820390671>3.0.CO;2-I","volume":"39","author":"B Fisher","year":"1977","unstructured":"Fisher B, Montague E, Redmond C, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer. 1977;39(6 Suppl):2827\u201339.","journal-title":"Cancer"},{"issue":"3","key":"318_CR17","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.3390\/curroncol30030235","volume":"30","author":"O Lovrics","year":"2023","unstructured":"Lovrics O, Tao B, Parvez E. Safety and accuracy of sentinel lymph node biopsy alone in clinically node-positive patients undergoing upfront surgery for invasive breast cancer: a systematic review. Curr Oncol. 2023;30(3):3102\u201310.","journal-title":"Curr Oncol"},{"issue":"2","key":"318_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10549-022-06699-w","volume":"196","author":"V Man","year":"2022","unstructured":"Man V, Luk WP, Fung LH, et al. The role of pre-operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;196(2):245\u201354.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"318_CR19","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1097\/JS9.0000000000000664","volume":"109","author":"Z Bi","year":"2023","unstructured":"Bi Z, Ren TY, Zhang ZP, et al. The management concept of breast cancer with clinically node-negative\/imaging node-positive disease. Int J Surg. 2023;109(11):3727\u20139.","journal-title":"Int J Surg"},{"issue":"8","key":"318_CR20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/jso.26840","volume":"125","author":"RL McCaffrey","year":"2022","unstructured":"McCaffrey RL, Thompson JL, Oudsema RH, et al. Management of early stage HER2 positive breast cancer and increased implementation of axillary imaging to improve identification of nodal metastasis. J Surg Oncol. 2022;125(8):1218\u201323.","journal-title":"J Surg Oncol"},{"issue":"5","key":"318_CR21","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1245\/s10434-024-15020-6","volume":"31","author":"CS Cortina","year":"2024","unstructured":"Cortina CS, Rogers CC, Teshome M. ASO author reflections: neoadjuvant systemic therapy and nodal management in cT1-2 N0 triple-negative breast cancer. Ann Surg Oncol. 2024;31(5):3196\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"318_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4274\/ejbh.galenos.2023.2023-3-5","volume":"19","author":"HA Abdulla","year":"2023","unstructured":"Abdulla HA, Salman AZ, Alaraibi SJ, et al. Risk factors associated with sentinel lymph node metastasis in clinically node-negative breast cancer. Eur J Breast Health. 2023;19(3):229\u201334.","journal-title":"Eur J Breast Health"},{"issue":"12","key":"318_CR23","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","volume":"7","author":"AV Barrio","year":"2021","unstructured":"Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event. JAMA Oncol. 2021;7(12):1851\u20135.","journal-title":"JAMA Oncol"},{"key":"318_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.936148","volume":"13","author":"SE Lee","year":"2023","unstructured":"Lee SE, Ahn SG, Ji JH, et al. Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1\u20132 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy. Front Oncol. 2023;13: 936148.","journal-title":"Front Oncol"},{"issue":"3","key":"318_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1245\/s10434-018-7059-4","volume":"26","author":"SE Tevis","year":"2019","unstructured":"Tevis SE, Bassett R, Bedrosian I, et al. Oncotypedx recurrence score does not predict nodal burden in clinically node negative breast cancer patients. Ann Surg Oncol. 2019;26(3):815\u201320.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"318_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10549-024-07328-4","volume":"206","author":"KJ Fairhurst","year":"2024","unstructured":"Fairhurst KJ, McIntosh SA, Cutress R, et al. Current axillary management of patients with early breast cancer and low volume nodal disease undergoing primary surgery: results of a United Kingdom national practice survey. Breast Cancer Res Treat. 2024;206(3):465\u201371.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"318_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1245\/s10434-015-4944-y","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie M, Mautner SK, Stempel M, et al. Does a positive axillary lymph node needle biopsy result predict the need for an axillary lymph node dissection in clinically node-negative breast cancer patients in the ACOSOG Z0011 era? Ann Surg Oncol. 2016;23(4):1123\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"318_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10549-020-05636-z","volume":"181","author":"TK Yoo","year":"2020","unstructured":"Yoo TK, Kang BJ, Kim SH, et al. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis. Breast Cancer Res Treat. 2020;181(2):403.","journal-title":"Breast Cancer Res Treat"},{"key":"318_CR29","doi-asserted-by":"crossref","unstructured":"Mamtani A, Barrio AV, Plitas G, et al. Sentinel lymph node biopsy for cN1 HR+\/HER- breast cancer patients with palpable adenopathy: results of a multicenter, single-arm clinical trial. In: Society of Surgical Oncology SSO 2025 Annual Meeting. Ann Surg Oncol. 2025;32(Suppl 1):1\u2013310.","DOI":"10.1245\/s10434-025-17184-1"},{"issue":"2","key":"318_CR30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.21037\/gs-22-480","volume":"12","author":"M Vernet-Tom\u00e1s","year":"2023","unstructured":"Vernet-Tom\u00e1s M, Argudo N, Jimenez M, et al. Accuracy of sentinel node mapping in patients with biopsy-proven metastatic axillary lymph nodes and upfront surgery: preliminary results of the multimodal targeted axillary surgery (MUTAS) trial. Gland Surg. 2023;12(2):140\u201351.","journal-title":"Gland Surg"},{"key":"318_CR31","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"318_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","volume":"10","author":"G Montagna","year":"2024","unstructured":"Montagna G, Mrdutt MM, Sun SX, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10(6):793\u20138.","journal-title":"JAMA Oncol"},{"key":"318_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","volume":"60","author":"WP Weber","year":"2021","unstructured":"Weber WP, Matrai Z, Hayoz S, et al. Tailored axillary surgery in patients with clinically node-positive breast cancer: pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57\u201318, ABCSG-53, GBG 101). Breast. 2021;60:98\u2013110.","journal-title":"Breast"},{"issue":"8","key":"318_CR34","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1245\/s10434-023-13191-2","volume":"30","author":"J Lee","year":"2023","unstructured":"Lee J, Jung JH, Kim WW, et al. Ten-year oncologic outcomes in T1\u20133N1 breast cancer after targeted axillary sampling: a retrospective study. Ann Surg Oncol. 2023;30(8):4669\u201377.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"318_CR35","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1245\/s10434-020-09228-5","volume":"28","author":"S Angarita","year":"2021","unstructured":"Angarita S, Ye L, R\u00fcnger D, et al. Assessing the burden of nodal disease for breast cancer patients with clinically positive nodes: hope for more limited axillary surgery. Ann Surg Oncol. 2021;28(5):2609\u201318.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"318_CR36","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/bjs\/znac305","volume":"109","author":"D Cocco","year":"2022","unstructured":"Cocco D, Shah C, Wei W, et al. Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer: a National Cancer Database analysis. Br J Surg. 2022;109(12):1293\u20139.","journal-title":"Br J Surg"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00318-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00318-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00318-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T23:02:33Z","timestamp":1758495753000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00318-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00318-7","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}